TABLE 2.
Reference | Population age (years) | Time range | Data source | Cancer type |
---|---|---|---|---|
Abrahão et al., 201522 | <1–19 | 1988–2011 | California Cancer Registry | APL |
Abrahão et al., 201523 | Only analyzed 0–19 data in review | 1988–2011 | California Cancer Registry | ALL |
Acharya et al., 201621 | 1–18 | 1995–2008 | Florida Cancer Data System, Texas Cancer Registry | ALL |
Austin et al., 201524 | ≤18 | 1995–2009 | Texas Cancer Registry | Non-CNS solid tumor malignancy |
Austin et al., 201625 | ≤18 | 1995–2009 | Texas Cancer Registry | CNS |
Bona et al., 20167,31 | 1–18 | 2000–2010 | Dana Farber Cancer Institute | ALL |
Bona et al., 202041 | ≤18 | 2005–2014 | Children’s Oncology Group, | High-risk neuroblastoma |
Pediatric Health Information System | ||||
Bona et al., 202136 | ≤18 | 2006–2015 | Center for International Blood and Bone Marrow Transplant Research | Generally mentioned “malignant disease” |
Byrne et al., 201135 | Only included <10, 10–19 data in review | 1998–2002 | Florida Cancer Data System | AML |
Colton et al., 201943 | Only analyzed 15–19 in review | 2007–2014 | SEER | Lymphoid leukemia, AML, HL, NH: (except Burkitt), astrocytomas, gliomas, hepatic carcinomas, malignant gonadal germ cell tumors, other and unspecified carcinomas |
Cooney et al., 201826 | 0–19 | 1988–2012 | California Cancer Registry | High-grade glioma, medulloblastoma |
Doganis et al., 201842 | 0–14 | 1990–2012 | SEER | Wilms tumor |
Dressler et al., 201737 | 0–19 | 1998–2011 | NCDB | Medulloblastoma |
Garner et al., 201739 | ≤21 | 1998–2012 | NCDB | WDTC |
Hamilton et al., 201627 | ≤18 | 1995–2009 | Texas Cancer Registry | Melanoma |
Kehm et al., 201828 | 0–19 | 2000–2012 | SEER | ALL, AML neuroblastoma, NHL, HL, astrocytoma, non-astrocytoma CNS tumors, non-rhabdomyosarcoma soft tissue sarcomas, rhabdomyosarcoma, Wilms tumor, osteosarcoma, germ cell tumors |
Kent et al., 200929 | 0–14 | 1996–2005 | California Cancer Registry | Leukemia (ALL, AML, CLL, CML) |
Khullar et al., 202038 | ≤21 | 2004–2015 | NCDB | HL |
Knoble et al., 201632 | 0–19 | 1973–2012 | SEER | AML |
Lee et al., 201745 | <15 | 2007–2009 | SEER | Leukemias, lymphomas, CNS neoplasms, neuroblastomas, PNS tumors, retinoblastomas, renal tumors, hepatic tumors malignant tumors, sarcomas, germ cell tumors, malignant epithelial neoplasms |
Mitchell et al., 202030 | 0–19 | 2000–2015 | SEER | CNS |
Penumarthy et al., 202044 | Only analyzed <15 in review | 2000–2015 | UC San Francisco Cancer Registry | Bone and soft tissue sarcomas |
Ribeiro et al., 201533 | 0–19 | 2000–2009 | SEER | Langerhans cell histiocytosis |
Schraw et al., 2020 | <20 | 1995–2011 | Texas Cancer Registry | ALL |
Siegel et al., 201940 | <20 | 2001–2008 | CDC NPCR | CNS |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CDC, Centers for Disease Control and Prevention; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CNS, central nervous system; HL, Hodgkin lymphoma; NCDB, National Cancer Database; NHL, non-Hodgkin lymphoma; NPCR, National Program of Cancer Registries; PNS, peripheral nervous system; SEER, Surveillance, Epidemiology, and End Results; WDTC, well-differentiated thyroid cancer.